TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31399438

Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily; n = 4,668)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo (n = 4,672)
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Liraglutide (n = 4,668)
Number of subjects: 9340
Study: 28009690

Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microneedling
Number of subjects: 30
Study: 26348751

Group type: EXPERIMENTAL
Intervention: 60 mg of elemental iron (as ferrous fumarate)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 22684652

Group type: EXPERIMENTAL
Intervention: Micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21659294

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard Clinical Case Management (SCCM)
Number of subjects: 198
Study: 18820317

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 168
Study: 17107402

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg plus montelukast 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg plus placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15174894

Group type: EXPERIMENTAL
Intervention: Oral modified-release clarithromycin 500 mg/day for 3 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11409816

Group type: EXPERIMENTAL
Intervention: Enhanced intervention, additional cost of $124.17
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention, cost of $187.52
Number of subjects: 0
Study: 9248762

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) 500 micrograms b.i.d. for 7 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) 1000 micrograms b.i.d. for 7 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) 400 micrograms b.i.d. for 7 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) 800 micrograms b.i.d. for 7 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) ED50
Number of subjects: 81

Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) ED50
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) morning plasma cortisol levels
Number of subjects: 81

Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) morning plasma cortisol levels
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) cortisol suppression 12-24 h after last dose
Number of subjects: 81

Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) cortisol suppression 12-24 h after last dose
Number of subjects: 81
Study: 8507346

Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3113399

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate 50 micrograms/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate 100 micrograms/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 23
Study: 28731871

Group type: EXPERIMENTAL
Intervention: Counselor‐Assisted Problem Solving (CAPS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study: 26546591

Group type: EXPERIMENTAL
Intervention: Probing dry weight and lowering home BP
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lowering home BP
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Uremic symptoms
Number of subjects: 133
Study: 24188897

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (100mg elemental Zn daily for 60 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study: 23276723

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12
Study: 20846599

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg maintenance dose (MD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg maintenance dose (MD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) + 10 mg maintenance dose (MD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel loading dose (LD)
Number of subjects: 100
Study: 18718780

Group type: EXPERIMENTAL
Intervention: Subantimicrobial doses of doxycycline for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 11
Study: 16423669

Group type: EXPERIMENTAL
Intervention: Color encoding of endocardial motion
Number of subjects: 117
Study: 15300731

Group type: EXPERIMENTAL
Intervention: EMF exposure from a 902 MHz mobile phone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 64
Study: 11780726

Group type: EXPERIMENTAL
Intervention: Video game training using the symbolic method with the intention of making progress in actual putting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video game training using the symbolic method with the intention of simply enjoying the game
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video game training using the analogue method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (enjoyment group) using the analogue method
Number of subjects: 0
Study: 9034286

Group type: EXPERIMENTAL
Intervention: IV rhG-CSF at dosages of 5 or 10 microg/kg a day for 10 or more days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IV rhG-CSF
Number of subjects: 12
Study: 8475720

Group type: EXPERIMENTAL
Intervention: Maxidex
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pred‐Forte 1%
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 3772891

Group type: EXPERIMENTAL
Intervention: Single perioperative dose of mezlocillin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Three doses of mezlocillin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Three doses of cefoxitin
Number of subjects: 158
Study: 31035841

Group type: EXPERIMENTAL
Intervention: Hypertonic (2.3% NaCl) sea water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic (0.9% NaCl) sea water
Number of subjects: 30
Study: 30041235

Group type: EXPERIMENTAL
Intervention: 10 revolutions during EBUS-TBNA
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 revolutions during EBUS-TBNA
Number of subjects: 150
Study: 26832658

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4) in patients without prior anti-VEGF treatment
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8) in patients without prior anti-VEGF treatment
Number of subjects: 865

Group type: COMPARATOR
Intervention: Macular laser photocoagulation in patients without prior anti-VEGF treatment
Number of subjects: 865
Study: 23897775

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 10 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 70
Study: 22293719

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (basal 12 ml/h; bolus 4 ml)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 3 ml/h; bolus 1 ml)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.4% ropivacaine
Number of subjects: 36
Study: 20598077

Group type: EXPERIMENTAL
Intervention: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units, subcutaneously once daily for 6 months.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo, subcutaneously once daily for 6 months.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 186
Study: 17637403

Group type: EXPERIMENTAL
Intervention: Postdischarge enoxaparin (40 mg once daily for 20 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (once daily for 20 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Postdischarge enoxaparin (40 mg once daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15310644

Group type: COMPARATOR
Intervention: NOBLOCK group (no neuromuscular blocking agent)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BLOCK group (cisatracurium prior to LMA insertion)
Number of subjects: 130

Group type: COMPARATOR
Intervention: NOBLOCK group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BLOCK group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 12374899

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9661545

Group type: EXPERIMENTAL
Intervention: Preemptive epidural bupivacaine (0.66 mL/kg 0.25%) with morphine (0.02 mg/kg) administered caudally before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postincisional administration of the same bupivacaine-morphine mixture after surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preemptive epidural bupivacaine with morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postincisional administration of the same bupivacaine-morphine mixture
Number of subjects: 60
Study: 7714226

Group type: EXPERIMENTAL
Intervention: Nefazodone 100 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2757895

Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Roferon-A) administered as an intra-muscular injection (3 x 10(6) iu) once-a-day over 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Roferon-A)
Number of subjects: 0
Study: 54852

Group type: EXPERIMENTAL
Intervention: Gelatin infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dextran 60 infusion
Number of subjects: 7
Study: 31253112

Group type: EXPERIMENTAL
Intervention: HealtheSteps™ program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 118
Study: 27894985

Group type: EXPERIMENTAL
Intervention: Retreatment for tuberculosis
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Patients aged 25-34 years
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Patients aged 35-44 years
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Patients aged 45-54 years
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Patients aged 55-64 years
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Patients aged >64 years
Number of subjects: 7980

Group type: EXPERIMENTAL
Intervention: Co-infected cases receiving antiretroviral therapy (ART)
Number of subjects: 7980
Study: 26423504

Group type: EXPERIMENTAL
Intervention: CHX group (0.12% chlorhexidine gluconate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Essential oils (EO) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC) group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tri group (triclosan)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hamamelis virginiana (HV) group
Number of subjects: 50
Study: 22576643

Group type: EXPERIMENTAL
Intervention: Immediate mobilization of the elbow joint
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Active mobilization after 2 days of sling use
Number of subjects: 180

Group type: COMPARATOR
Intervention: Immobilization in a cast for 7 days (Control)
Number of subjects: 180
Study: 21426603

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 20054744

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17224860

Group type: EXPERIMENTAL
Intervention: Isoflavone treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study: 15370901

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 11686419

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled fluticasone propionate (FP) 44 microg, two puffs twice daily for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (ZK) 20 mg, twice daily for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 18
Study: 11301564

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg every 3 hours (six times a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg four times a day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg three times a day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single 5-mg/kg intravenous infusion of ganciclovir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 6,000 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3,000 mg/day and 4,000 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 4,000 mg/day and 6,000 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher dosages of ganciclovir
Number of subjects: 24
Study: 7943789

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 3062257

Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) for stage I/IIA
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) and COMP therapy (2 cycles) for stage IIB/IIIA
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OPA therapy (2 cycles) and COMP therapy (4 cycles) for stage IIIB/IV
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Radiotherapy (dosage of 35, 30 or 25 Gy depending on chemotherapy extent)
Number of subjects: 103
Study: 30237584

Group type: EXPERIMENTAL
Intervention: rs11749255 in MSX2
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: IFLTD1 rs6487504
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: PTPRD rs324498
Number of subjects: 1779

Group type: EXPERIMENTAL
Intervention: Genetic risk score for RHTN
Number of subjects: 1779
Study: 28886018

Group type: EXPERIMENTAL
Intervention: Oxford Elbow Score (OES)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quick Disabilities of the Arm, Shoulder, and Hand (Quick‐DASH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mayo Elbow Performance Index, pain (VAS), Short Form‐36, EuroQol‐5D
Number of subjects: 100
Study: 26147010

Group type: EXPERIMENTAL
Intervention: P2G12 (monoclonal antibody derived from transgenic tobacco)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 23453465

Group type: EXPERIMENTAL
Intervention: Lateral position (Group L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sitting position (Group S)
Number of subjects: 100
Study: 20034685

Group type: COMPARATOR
Intervention: Metformin 850 mg/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg/d + Atorvastatin 10 mg
Number of subjects: 35
Study: 19833593

Group type: EXPERIMENTAL
Intervention: Continuous TENS (CTENS) and pharmacologic analgesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intermittent TENS (ITENS) and pharmacologic analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo TENS (PTENS) and pharmacologic analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pharmacologic analgesia alone (control)
Number of subjects: 100
Study: 16918659

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) of ketamine before surgery (Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) of ketamine after surgery (Group III)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No ketamine (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No unwanted side effects noted in any group
Number of subjects: 90
Study: 15479482

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg I.V. every 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (I.V. every 2 weeks)
Number of subjects: 0
Study: 10976977

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (10% dextrose and 0.075% xylocaine in bacteriostatic water)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (0.075% xylocaine in bacteriostatic water)
Number of subjects: 27
Study: 9302444

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg intramuscularly every 2 weeks for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo intramuscularly every 2 weeks for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8391304

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms kg−1) as a single prophylactic 5-min infusion
Number of subjects: 281

Group type: COMPARATOR
Intervention: High-dose metoclopramide (loading dose of 3 mg kg−1 followed by maintenance dose of 4 mg kg−1 infused over 8 h) plus dexamethasone (12 mg as a 30-min infusion)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 281

Group type: COMPARATOR
Intervention: High-dose metoclopramide plus dexamethasone
Number of subjects: 281
Study: 3540229

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pindolol 7.5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Labetalol 200 mg twice daily
Number of subjects: 0
Study: 30216749

Group type: EXPERIMENTAL
Intervention: Diploma students (GNM)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Bachelor students (B.Sc. nursing)
Number of subjects: 633
Study: 27312945

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular testosterone undecanoate)
Number of subjects: 101
Study: 24954162

Group type: EXPERIMENTAL
Intervention: DHA supplementation (almond-based beverage enriched with DHA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (almond-based beverage without DHA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both DHA and placebo groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training season
Number of subjects: 15
Study: 22456632

Group type: EXPERIMENTAL
Intervention: 2-year school-based physical activity intervention
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study: 20550650

Group type: EXPERIMENTAL
Intervention: Chronic Care Model implemented by trained practice nurse
Number of subjects: 336
Study: 19001963

Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Emergent cricothyrotomy and tracheostomy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anterior or posterior packing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Penetrating wounds management
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Blunt trauma management
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 90
Study: 15953008

Group type: EXPERIMENTAL
Intervention: Combination of asparaginase (ASP) and steroids during the postinduction intensification phase, with high-risk patients receiving thrice the steroid dose compared to standard-risk patients.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Older patients (≥10 years) receiving the same treatment.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-risk (HR) treatment group receiving the same treatment.
Number of subjects: 91
Study: 12748666

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) treatment for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no IFN treatment).
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) treatment.
Number of subjects: 106
Study: 12810146

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 171
Study: 9579718

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg bd
Number of subjects: 60

Group type: COMPARATOR
Intervention: co-amoxiclav 625 mg tds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: co-amoxiclav
Number of subjects: 60
Study: 7644852

Group type: EXPERIMENTAL
Intervention: Buflomedil (400 mg in bolus)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (200 mg in bolus)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (500 micrograms in bolus)
Number of subjects: 16
Study: 2528004

Group type: EXPERIMENTAL
Intervention: TE‐031 (clarithromycin) at a daily dosage of 400 mg in 2 divided doses
Number of subjects: 302

Group type: COMPARATOR
Intervention: JM (josamycin) at a daily dosage of 1,200 mg in 3 divided doses
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: TE‐031 (clarithromycin)
Number of subjects: 302

Group type: COMPARATOR
Intervention: JM (josamycin)
Number of subjects: 302